Jpmorgan Chase & CO Eq Rx, Inc. Transaction History

Jpmorgan Chase & CO

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$1.66 - $2.31 $44,300 - $61,646	-26,687 Reduced 1.56%	1,683,485 $3.74 Million
Q2 2023 Aug 11, 2023	BUY	$1.61 - $1.96 $86,242 - $104,991	53,567 Added 3.23%	1,710,172 $3.18 Million
Q1 2023 May 18, 2023	BUY	$1.8 - $2.83 $479,579 - $754,005	266,433 Added 19.17%	1,656,605 $3.21 Million
Q1 2023 May 11, 2023	SELL	$1.8 - $2.83 $358,718 - $563,985	-199,288 Reduced 12.54%	1,390,172 $2.7 Million
Q4 2022 Feb 13, 2023	BUY	$2.05 - $5.5 $114,535 - $307,290	55,871 Added 3.64%	1,589,460 $3.91 Million
Q3 2022 Nov 14, 2022	SELL	$0.94 - $5.99 $22,001 - $140,201	-23,406 Reduced 1.5%	1,533,589 $7.59 Million
Q2 2022 Aug 11, 2022	BUY	$3.2 - $5.69 $4.98 Million - $8.86 Million	1,556,995 New	1,556,995 $7.3 Million

67.8M

Ticker EQRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 448,140,992
Description
EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company's pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EG...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.